OneMedNet Corp is classed by the SEC under Services-Commercial Physical & Biological Research (industry code 8731), based in Surrey, GB. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $1 million and a loss of $3 million (its filed statements).
Pre-revenue companyServices-Commercial Physical & Biological ResearchSurrey, GBfilings since 20218 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 8731), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 3.4 out of ten, 8 of 9 metrics filed and 1 estimated: past 1.5 out of ten, present 1.9 out of ten, future 5.9 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 0.4 out of ten. 27 warning events since 2021; the latest 2026-04-20. 4th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 2.8 out of ten. +5.6% a year over 4 filed years; profitable in 0 of 4. 28th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 0.4 out of ten. CrossAssetData estimate 0.4/10, confidence 35 of 100 (one part). 4th percentile among 12 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 1.3 out of ten. Leverage 238%: owes 238¢ per asset dollar. 13th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 3.8 out of ten. bottom 38% of 12 in its family; net margin -206.1%. 38th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 1.5 out of ten. bottom 15% of 8 in its family for leadership; chief executive since 2025. 15th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 3.6 out of ten. bottom 36% of 12 in its family for room to expand. 36th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 6.0 out of ten. top 40% of 12 in its family for growth drivers. 60th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 8.9 out of ten. top 11% of 11 in its family for expectations against reality. 89th percentile among 11 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-30 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-14 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2024-05-23 (on EDGAR). Newest filing: Form 4, 2026-10-09. Filings on record since 2021. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Data Delivery Revenue 92%, Subscription Revenue 8%. As tagged in its annual report (Form 10-K, filed 2026-03-30).
Who runs it
Green, Aaron (Chief Executive Officer); Golden, Robert Lawrence (Chief Financial Officer); Yu, Jeffrey (Chief Medical Officer); Kosasa, Thomas (director); Alleyne, Kenneth (director); Casaburi, Eric (director); Clarke, Jair (director); Mccraw, Sherry Coonse (director); Zeinfeld, Andrew B (director). 9 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-09.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.